Key facts
- This page summarizes Anthony S. Marucci's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2024, 08:01.
Anthony S. Marucci - 11 Nov 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- PRESIDENT & CEO, Director
- Issuer ticker
- CLDX
- Reported as of
- 11 Nov 2024
- Net transaction value
- +$308,430
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2024, 08:01:10 UTC
- Prior SEC filing
- 17 Jun 2024
- Next SEC filing
- 09 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Anthony S. Marucci
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anthony S. Marucci filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 12 Nov 2024.
Change
- Previous filing in this sequence was filed on 17 Jun 2024.
- Current net transaction value: +$308,430.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Purchase
- Transaction value
- $308,430
- Shares
- +11,500
- Change %
- +40%
- Price
- $26.82
- Shares after
- 40,284
- Date
- 11 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Includes 1,092 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.